GSK, Inventor Urge Fed. Circ. To Review Tafas V. Doll

By Erin Coe

Law360, New York (June 04, 2009, 12:00 AM ET) -- A federal appeals court’s decision that upheld most of the U.S. Patent and Trademark Office’s rules putting new restrictions on patent applicants improperly expands the agency’s authority and threatens to stifle innovation, according to two petitions calling for a review of the controversial Tafas v. Doll ruling.

Pharmaceutical firm GlaxoSmithKline PLC and inventor Triantafyllos Tafas filed petitions in the U.S. Court of Appeals for the Federal Circuit on Wednesday seeking a rehearing or rehearing en banc of the March 20 decision that sided for the most...
To view the full article, take a free trial now.

Already a subscriber? Click here to login

You must correct or enter the following before you can submit this form:

All fields required

  5. Required

Only Law360 gives you:

Non-stop coverage of high-stakes litigation across 30 practices

Real-time tracking and reports on 10,000+ companies, firms and industries

Over 80,000 attorney profiles with neutral data collected from active lawsuits

Research tools to find cases, court documents, attorneys and companies

Customized feeds and alerts that can easily be shared with colleagues

In-depth expert analysis from high-profile attorneys at top firms

Access to our vault with over 75,000 original articles